The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1420
ISSUE1420
July 8, 2013
Ospemifene (Osphena) for Dyspareunia
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Ospemifene (Osphena) for Dyspareunia
July 8, 2013 (Issue: 1420)
The FDA has approved ospemifene (os pem’ i feen;
Osphena – Shionogi), an estrogen agonist/antagonist,
for oral treatment of moderate to severe dyspareunia in
postmenopausal women. Ospemifene is the fourth estrogen
agonist/antagonist to be...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.